StageGrant - II | Alive
Last Raised$9.2M | 1 yr ago
Sapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small-molecule biomarker profiling. Its platform combines advanced mass spectrometry technologies, biocomputational learning, and a proprietary Human Biology Database to discover circulating biomarkers of health, disease, and drug responsiveness. It was founded in 2020 and is based in San Diego, California.
Sapient's Product Videos
Compete with Sapient?
Ensure that your company and products are accurately represented on our platform.
Sapient's Products & Differentiators
Rapid Liquid Chromatography-Mass Spectrometry (rLC-MS) Technologies
A proprietary technology that enables ultra high throughput, population-level small molecule biomarker discovery.
Latest Sapient News
Jul 11, 2022
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022 07:48 AM Eastern Daylight Time SAN DIEGO--( BUSINESS WIRE )--Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a new grant from the Bill & Melinda Gates Foundation to use its rapid liquid chromatography-mass spectrometry ( rLC-MS ) based platforms for population-scale discovery metabolomics analysis in broad support of the foundation’s programs across maternal, newborn, and child health, nutrition, and vaccine development, among other priority research areas. A large portion of the $9.2 million grant will provide bioanalytical capacity for studies aimed at identifying metabolic pathways and biomarkers to inform novel nutritional, disease-prevention, and disease-treatment interventions for health issues that disproportionately affect women and infants in developing countries. Sapient’s untargeted, high throughput discovery metabolomics platform will be applied to analyze tens of thousands of biosamples collected through programs conducted by Bill & Melinda Gates Foundation grantees in its Global Health Discovery Collaboratory . In addition to rLC-MS analysis, the new grant will enable Sapient to provide grantees with support for biocomputational analyses and molecule identification of key discovered biomarkers, as well as capacity building for analytical and data handling capabilities among the grantees. The new grant represents an extension of prior funding awarded to Sapient from the Bill & Melinda Gates Foundation which was used to provide population-scale metabolomics discovery analyses for 27 independent global health discovery and translation projects initiated by the foundation’s grantees in the areas of COVID-19, maternal, newborn, and child health, infectious disease, and hypoxia. Sapient’s support in these programs led to key discoveries including identification of novel biomarkers of early-stage disease, biological processes, and protective factors that are being used to develop diagnostic field tests and optimal disease prevention and treatment interventions. “We are grateful for the opportunity to continue our exciting collaborations with the Bill & Melinda Gates Foundation and to support the incredible work being done through their grantees to tackle critical global health challenges in underserved populations,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “This grant allows us to perform population-level analyses for a highly unique scale of discovery that amplifies our ability to identify robust, specific small molecule biomarkers of health and disease. Most importantly, it enables us to work with the Gates Foundation and its grantees to interpret our discoveries and make them actionable in advancing their research to impact global health outcomes.” About Sapient Sapient is an end-to-end biomarker discovery organization dedicated to accelerating the mapping of circulating chemistries in humans through rapid, large-scale small molecule biomarker profiling. Its platform combines advanced mass spectrometry technologies – able to assay >11,000 small molecule factors per biosample – biocomputational learning, and a proprietary Human Biology Database with data from several hundred thousand biosamples to discover circulating biomarkers of health, disease, and drug responsiveness at unprecedented speed and scale. For more information, visit sapient.bio . Contacts
Sapient Frequently Asked Questions (FAQ)
When was Sapient founded?
Sapient was founded in 2020.
Where is Sapient's headquarters?
Sapient's headquarters is located at 10421 Wateridge Circle, San Diego.
What is Sapient's latest funding round?
Sapient's latest funding round is Grant - II.
How much did Sapient raise?
Sapient raised a total of $13.8M.
Who are the investors of Sapient?
Investors of Sapient include Bill & Melinda Gates Foundation.
Who are Sapient's competitors?
Competitors of Sapient include Metabolon and 2 more.
What products does Sapient offer?
Sapient's products include Rapid Liquid Chromatography-Mass Spectrometry (rLC-MS) Technologies and 3 more.
Who are Sapient's customers?
Customers of Sapient include Bill & Melinda Gates Foundation.
Compare Sapient to Competitors
Molecular You analyzes a range of biomarkers to show health risks and what the user can do about it. Its preventive health assessment analyze not only genetics, but also metabolites, proteins, nutrients, and toxins to give the user the full picture. Then, it designs a personal diet and fitness plan to help the user stay healthy.
Atropos Health is a developer of a physician consultation service powered by research-grade, real-world data. Using millions of anonymized patient records, the company helps providers answer clinical questions that have fallen through the cracks of the evidence-based literature. Atropos empowers more robust research and effective care delivery by leveraging insights from free-text notes and other non-standard data entries that often go overlooked. The company was founded in 2019 and is based in New York, New York.
ElexoPharm is a German biotech company, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University. ElexoPharm is focused on the preclinical discovery and optimization of drugs for human diseases, which are currently not or insufficiently treatable with existing drugs.
Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.
Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation, an area in which it has developed considerable expertise.
Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.